Key facts
- It has raised $1.9M across 1 recorded rounds; the latest was Seed Round ($1.9M) in Feb 2022.
- Notable investors include CONNECT (San Diego).
- A28 Therapeutics has filed 1 Form D with the SEC, most recently Jan 2025 ($1.9M sold to 26 investors).
- Status: Privately Held (backing).
Investors
1- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for A28 Therapeutics
Funding rounds
1 roundsAbout A28 Therapeutics
Operator of a clinical-stage biopharmaceutical company intended to provide treatment for cancer. The company focuses on developing safe and effective new treatments with multiple classes of cancer medications, including immuno-oncology medications and chemotherapy, enabling patients to access improved medical care.
- Sector
- Healthcare
- HQ
- La Jolla, CA, United States
- Founded
- 2021
- Employees
- 7
- Website
- a28therapeutics.com/
- Ownership
- Privately Held (backing)
A28 Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in A28 Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on A28 Therapeutics in its N-PORT filings yet. We sweep new filings monthly.